INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Portfolio Update as at 31 October 2016
Net Assets |
£217m |
Net Assets per share |
577p |
Share price |
535p |
Total value of unquoted investments |
£31m |
Total number of portfolio companies |
77 |
Top Ten Holdings
Company Name |
% NAV |
Celgene |
7.0 |
Biogen |
6.7 |
Incyte |
6.6 |
Regeneron |
5.7 |
Gilead |
4.9 |
Tesaro |
4.3 |
Genmab |
4.3 |
Alexion |
4.0 |
Actelion |
3.4 |
Entellus |
3.1 |
|
----------- |
Total |
50.0 |
Geographical Allocation |
% NAV |
US & Canada |
80 |
Europe & UK |
20 |
|
----------- |
Total |
100 |
Quoted/Unquoted Allocation |
% NAV |
Quoted |
86 |
Unquoted |
14 |
|
----------- |
Total |
100 |
NAV % Market Cap |
% NAV |
Large Cap >USD10BN |
52 |
Mid Cap =USD1-10BN |
24 |
Small Cap <USD1BN |
24 |
|
----------- |
Total |
100 |
NAV % by Therapeutic Areas |
% NAV |
Oncology |
36 |
Orphan |
16 |
Inflammation |
10 |
Ophthalmology |
7 |
CNS |
6 |
Medtech |
4 |
Other |
21 |
|
----------- |
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
17 NOVEMBER 2016